Search

everythinglearnresearchcommunity

for

Search:↓

Hyperbaric Oxygen Therapy (HBOT) is discussed as a potential treatment for androgenic alopecia due to its ability to reverse hypoxia and promote angiogenesis. The conversation explores its potential benefits for hair loss, though no studies have been conducted on this application yet.

The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.

A user noticed a color change in their hair loss solution containing minoxidil, finasteride, retinoic acid, and hydrocortisone after storing it for several months. They are concerned about the effectiveness of the solution due to potential oxidation.

The user experiences irritation from alcohols in minoxidil and is considering alternatives like trichosol mixed with polyethylene glycol or DMSO. They seek advice on the best nonirritating option.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.

Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).

The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

Nanoxidil, a minoxidil derivative, is being discussed as a potential hair loss treatment. Users are curious about its effectiveness and side effects compared to minoxidil, with some noting it includes additional ingredients like caffeine.

The conversation is about finding shampoos with Piroctone Olamine in the US for itch relief, as the user has not found relief with Keto shampoo, oral Dutasteride, and oral Minoxidil. Users suggest alternatives like Neutrogena T/Gel and online options, but note availability and price issues.

The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.

Mixing 2.5mg of minoxidil powder with 150ml of water seems to eliminate its blood pressure effects, causing only a brief 20-second hypertension. The reason for this effect is unclear.

The conversation discusses using topical finasteride with propylene glycol, which causes scalp dryness or dandruff. The user also uses Nizoral, Nioxin, and DHT oil, and considers using a scalp conditioner to alleviate dryness.

The conversation is about the accidental taste of Nizoral shampoo, which contains ketoconazole, during hair washing. Specific hair loss treatments mentioned are Minoxidil, Finasteride, and RU58841.

The conversation is about finding a pure high molecular weight hyaluronic acid for the scalp after microneedling. A user suggests using a product from The Ordinary.

A 30-year-old male with thinning hair and an itchy, oily scalp found that hydrocortisone cream eliminated dandruff and itching and seemed to thicken his hair. He avoided minoxidil and finasteride due to potential side effects and noted that Nizoral and Head & Shoulders worsened his symptoms.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

The user has been mixing finasteride with stemoxydine for hair loss and is considering switching to a less expensive product with a different ingredient list. They are questioning if the new product's higher water content compared to alcohol will affect the finasteride's solubility.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Nizoral causes scalp and face itchiness and flakes. Piroctone olamine is suggested as an alternative.

The conversation is about a user seeking advice on adding GHK-Cu to RU58841 for hair loss treatment, while already using oral minoxidil, dutasteride, ketoconazole shampoo, and considering LLLT. They are unsure about the concentration and carrier solution for GHK-Cu.

Salicylic acid in Nioxin shampoo may reduce minoxidil effectiveness by inhibiting sulfotransferase activity, potentially causing hair loss. Users suggest stopping salicylic acid use or trying alternative treatments like high-concentration tretinoin or medicated minoxidil/finasteride shampoos.

The conversation discusses the use of pyrrolidinyl diaminopyrmidine oxide (triaminodil) compared to minoxidil for hair loss treatment. The user is considering switching from 5% minoxidil to a product containing 5% triaminodil.

RU-58841 does not dissolve well in common Minoxidil solutions due to water content, requiring a 70/30 ethanol/propylene glycol mix. Users report using separate solutions for RU-58841 and finasteride/Minoxidil for better results.

Hydrocortisone helps relieve scalp itchiness, possibly caused by minoxidil. Users discuss its effectiveness for managing this side effect.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

Efforts to find a Canadian dermatologist in the US to prescribe H&W's topical finasteride for hair loss. The user is willing to fund a crowd-share effort to identify prospects.